{"id":"W2254400861","doi":"10.1200/jco.2015.33.18_suppl.lba8512","title":"Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Neutropenia; Pomalidomide; Population; Refractory (planetary science); Nausea; Gastroenterology; Clinical endpoint; Adverse effect; Carfilzomib; Multiple myeloma; Phases of clinical research; Surgery; Lenalidomide; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001618312,0.00198783,0.002269148,0.0004841344,0.0004563457,0.001004158,0.0009912254,0.001289944,0.006375724],"category_scores_gemma":[0.0008067061,0.0009702375,0.00128172,0.0004186723,0.0007755399,0.0009029472,0.0004637177,0.003407073,0.001791099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001093283,"about_ca_system_score_gemma":0.002014505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001193021,"about_ca_topic_score_gemma":0.003007302,"domain_scores_codex":[0.9996369,0.0001645118,0.00001349768,0.00007398444,0.00003345778,0.00007764868],"domain_scores_gemma":[0.9993044,0.00008355418,0.0001343913,0.00004919036,0.00003802859,0.0003905008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7141936,0.1402358,0.00857636,0.0007362747,0.001351538,0.0003317435,0.0003404719,0.003073642,0.05268127,0.0003931546,0.01082643,0.06725968],"study_design_scores_gemma":[0.7001971,0.2852249,0.00846436,0.00002191927,0.0002337195,0.0002120607,0.00004039457,0.001100123,0.001753422,0.0001751301,0.00255369,0.0000230826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849172,0.00179859,0.0008305481,0.0007713286,0.0002173135,0.005497952,0.003075338,0.0001845846,0.002707032],"genre_scores_gemma":[0.9735698,0.001815918,0.002944004,0.002092247,0.0003362028,0.006479728,0.006342414,0.00006684478,0.006352826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006375724,"threshold_uncertainty_score":0.02132893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2338223455922452,"score_gpt":0.5029430214787639,"score_spread":0.2691206758865187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}